课题基金 / 基金详情

ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM

ANTISENSE INHIBITION OF RETINAL GLUTAMATE METABOLISM
视网膜谷氨酸代谢的反义抑制
批准号:
6384239
负责人:
John Danias
金额:
$16.66万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-01 至 2004-07-31

项目摘要

项目成果

John Danias的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this K08 project is to test one of the two major current hypotheses about the role of glutamate in glaucomatous retinal ganglion cell (RGC) death. According to this hypothesis one result of elevated IOP is a derangement of the glutamate metabolic cycle in RGCs. This derangement results in glutamate excitotoxicity that has a primary role in the pathogenesis of glaucoma. Aim 1 and 2 of this project test the second component of this hypothesis; aim 3 tests the first component. Aim 1 is to determine the effects of a deranged glutamate metabolic cycle in the retina on the RGC function and survival. Antisense oligonucleotides to the glutamate metabolizing enzymes, glutamate dehydrogenase (GDH) and glutamine synthetase (GS) and to glutamate transporters (GLAST) will be used to inhibit glutamate metabolism and uptake in RGCs. Their effects will be determined in tissue culture and then following intra-vitreal administration rats to assess RGC survival, activities and amounts of GDH. GS and GLAST, intra-vitreal glutamate concentrations, and visual function by electroretinography. Aim 2 tests whether glutamate antagonists and anti-apoptosis agents can reverse the effects of a deranged glutamate cycle in the retina caused by the antisense oligonucleotides. Aim 3 is to determine whether changes in the glutamate metabolic cycle similar to those induced by the use of antisense oligonucleotides to GDH, GS and GLAST are present in a chronically elevated IOP model of glaucoma in rats. The K08 candidate has recently completed a clinical fellowship in the field of glaucoma and has begun a tenure track academic career in Mt. Sinai School of Medicine. While he does have some prior fundamental research experience, in order to embark upon the proposed studies he must first strengthen his skills in the areas of antisense design and pharmacokinetics and in some specific methods that will be used in testing the animals and assessing the outcomes. Mentoring will be provided by senior scientists, experts in these areas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue plasminogen activator for the treatment of glaucoma
Gene therapy to treat glaucoma by reducing intraocular pressure
  • 批准号:
    10323639
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    John Danias
  • 依托单位:
Complement activation in glaucoma
  • 批准号:
    8135346
  • 项目类别:
  • 资助金额:
    $60.57万
  • 财政年份:
    2004
  • 负责人:
    John Danias
  • 依托单位:
Complement activation in glaucoma
  • 批准号:
    8306579
  • 项目类别:
  • 资助金额:
    $24.13万
  • 财政年份:
    2004
  • 负责人:
    John Danias
  • 依托单位:
海外基金